Cepheid to es­tab­lish plant for Xpert MTB/ RIF tests in In­dia

BioSpectrum (India) - - SUPPLIER NEWS -

US-based lead­ing molec­u­lar di­ag­nos­tics com­pany, Cepheid Inc. (a wholly owned sub­sidiary of Dana­her) un­veiled its new­est con­fig­u­ra­tion in the GeneXpert fam­ily of sys­tems, the GeneXpert Edge, in In­dia re­cently. The com­pany also an­nounced its ‘Make in In­dia’ ini­tia­tive by an­nounc­ing plans to es­tab­lish their man­u­fac­tur­ing foot­print in the coun­try for Xpert MTB/ RIF test car­tridges which run on the GeneXpert Sys­tem. More than 1,200 Cepheid’s GeneXpert Sys­tems have been in­stalled in the last 2 years at var­i­ous Re­vised Na­tional Tu­ber­cu­lo­sis Con­trol Pro­gram (RNTCP) sites in the coun­try and more than 2.5 mil­lion car­tridges were supplied last year at var­i­ous cen­tres of Cen­tral TB Di­vi­sion (CTD). The GeneXpert Edge is ex­pected to be avail­able in In­dia later this year. The GeneXpert Edge is a por­ta­ble, easy-to-use sys­tem, de­vel­oped specif­i­cally for nearpa­tient test­ing, to help sup­port a one visit test-and-treat ap­proach. With al­most 17,000 sys­tems in 182 coun­tries, the GeneXpert Sys­tem is the world’s most pop­u­lar molec­u­lar di­ag­nos­tics sys­tem. Its mo­du­lar con­fig­u­ra­tion makes it the most scal­able plat­form avail­able, de­liv­er­ing the abil­ity to process from one to eighty tests si­mul­ta­ne­ously — en­abling ac­cu­rate, fast, and cost-ef­fec­tive test re­sults in both lower vol­ume pointof-care set­tings and higher vol­ume ref­er­ence lab­o­ra­to­ries.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.